Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LVGN3616 and LVGN6051±LVGN7409 Combinations in Metastatic Solid Tumors
NCT05075993Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2021
- Primary completion
- Feb 2027
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of LVGN3616, exlinkibart and LVGN7409 in solid tumor, esophageal cancer, gastric cancer (GC) and 5 more (4 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose / Recommended Phase 2 Dose at 1 year. Started Nov 2021; status: active, not recruiting.
02
Drugs
LVGN3616exlinkibartLVGN7409
03
Conditions
solid tumoresophageal cancergastric cancer (GC)head and neck carcinoma (HNC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05075993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05075993.